question due to the lack of a strict correlation between S6 phosphorylation and 5ЈTOP mRNA translation [12] [13] [14] .
Interestingly, the degree of S6 phosphorylation in S6K1 knockout mice is comparable to that in wild-type mice, suggesting that the highly homologous S6K2 (70% percent overall identity and 85% similarity) is compensating enzymatically for the lack of S6K1 [6]. Surprisingly, knockout of S6K2 results in no defects in cell or organism size, despite a reduction in S6 phosphorylation [14] . Collectively, these results imply that the small mouse phenotype is unique to disruption of the S6K1 allele and does not derive from a lack of S6 phosphorylation. Furthermore, the S6K1 phenotype predicts that there exist targets of S6K1 important for organism size control upon which S6K2 does not act. Although several new S6K1 substrates have been reported [3] , none has been shown to be specific to S6K1 or to be involved in cell growth control. Hence the question remains: how does S6K1 regulate cell growth?
We report here the isolation of a novel protein, SKAR (for S6K1 Aly/REF-like target), which interacts with and is a substrate of S6K1 but not S6K2. SKAR shares sequence homology with members of the Aly/REF family of RNA binding proteins, which couple transcription, pre-mRNA splicing, and nucleo-cytoplasmic mRNA transport [15] . SKAR is phosphorylated by S6K1 in vitro on sites that are mitogen regulated and rapamycin sensitive in vivo. RNA interference (RNAi)-mediated reduction of S6K1 but not S6K2 reduces the amount of SKAR phosphorylation, as determined by quantitative mass spectrometry. Decreasing SKAR or S6K1 levels by RNAi makes cells smaller, suggesting that SKAR is a target of S6K1 in cell growth control. These data suggest that cell growth regulation by the mTOR and PI3K pathways involves more than just translational control but may also impinge on the mRNA biosynthetic machinery.
Results

Isolation of a Predicted RNA Binding Protein that Interacts with S6K1 and Not S6K2
To identify novel targets of S6K1, we performed twohybrid screening of a mouse embryonic library [16] and did interact with S6K2⌬NT/CT, indicating that this construct is functional (data not shown). Clone 49 did not interact with the S6K1 C terminus, further confirming the specificity of the interaction. Together, these data Sequence database searches reveal clone 49 to be a partial clone ( Figure 1B) Figure 3C ; lanes 4-6). An even (Figure 2A Fig-4D ). Mutation of either serine 383 or 385 in this motif to ure S2). Mass spectrometry reveals phosphorylation at alanine resulted in reduced phosphorylation and mutation S383 and at S385, but not simultaneous phosphorylation of both abolished phosphorylation, indicating that these at both S383 and S385 (Supplemental Figure S3) . The sites are phosphorylated by S6K1 in vitro.
simplest interpretation of these results is that SKAR can be phosphorylated either at S383 or at S385, but not both, and that mutation of either serine residue affects Phosphorylation of SKAR In Vivo the ability of S6K1 to recognize the nonmutated serine Employing mass spectrometry, we identified several in vivo phosphorylation sites in SKAR, at residues S127, residue as a phosphorylation site. To address whether SKAR is specifically a substrate data provide strong evidence that SKAR is a physiological substrate of S6K1, but not S6K2. of S6K1 and not S6K2 in vivo, we employed quantitative mass spectrometry. To quantitate phosphorylation of SKAR on S383 or S385, we mixed isotope ( p70 and p85 isoforms with siRNA decreases cell size since we see a decreased rate of passage through S phase as measured by bromodeoxyuridine (BrdU) incorrelative to cells treated with the control siRNA ( Figures  6A, left, and 6B) . Reduction of SKAR likewise decreases poration (Table 2) . cell size (Figures 6A, right, and 6B) . Western blotting indicates that the knockdown of S6K1 and SKAR is not Discussion complete (Figure 6C) , suggesting that the effects on cell size shown are an underestimate of the potency of these We report here the identification of SKAR, a novel binding partner and substrate for S6K1. SKAR binds the genes. The observed decreases in size do not appear to occur because of a faster rate of passage through activated, hyperphosphorylated form of S6K1. Binding occurs within the catalytic and/or linker domains of the cell cycle permitting insufficient time for cell growth, 
